A study is currently ongoing in four centres in Australia, testing the effectiveness of a synthetic cannabis gel in reducing anxiety levels in children with learning disabilities, such as fragile X syndrome. Fragile X syndrome is a genetic disorder that can cause developmental delays, including learning delays and anxiety.
The gel contains cannabidiol (CBD), a compound found in cannabis that doesn’t produce the psychoactive effects commonly associated with its recreational use. Early research shows CBD has the potential to relieve anxiety, making it a promising treatment option for them.
Children with fragile X syndrome and similar conditions often have a hard time managing behavioural issues that stem from their learning disability, and their loved ones may find it challenging to find an effective way to help them. In a pilot study, a young man named Tom Mikkelsen had received the gel and showed improved concentration and reduced anxiety, according to his mother.
The study aims to assess the effectiveness of the CBD gel in dealing with the behavioural symptoms of fragile X, primarily anxiety, social anxiety, and irritability. The study’s preliminary results suggest that CBD medication has great potential in pediatrics in managing anxiety among children with developmental delays, Hughes Heussler, an associate professor of Queensland Children’s Hospital, said.
Currently, there are no core medications that target behavioural difficulties associated with fragile X. Researchers also believe that this study could show promising results for the treatment approach to other developmental delay conditions. Patients are being compared to a placebo.
If this trial succeeds, it could bring hope to the estimated 90,000 Australians suffering from this learning disability or carriers of the condition. For more information on the study, please visit the official trial website.
Stay informed by signing up to receive our daily newsletters and breaking news alerts, sent straight to your inbox.